Combined application of vaccine that contains RM-1 cells which expressed 4-1BBL with CTLA-4 blockade can induce the regression of prostate cancer cells, showing the treatment potency of 4-1BBL in cancer immunotherapy (69). This evidence concerns the gene CTLA4 and cancer.